IV-01 Alberto Russu Integration of response, tolerability and dropout in flexible-dose trials: a case study in depression Thursday 15:05-16:20 |
IV-02 Tarjinder Sahota Parameterisation of biomarker response in the assessment of long term safety Thursday 15:05-16:20 |
IV-03 Franziska Schädeli Stark A semi-mechanistic population pharmacokinetic model for trastuzumab emtansine (T-DM1) antibody-drug conjugate and total antibody in patients with metastatic breast cancer (mBC) Thursday 15:05-16:20 |
IV-04 Andre Schäftlein Comparison of elimination and absorption pharmacokinetics of linezolid in cystic fibrosis patients by three nonlinear models Thursday 15:05-16:20 |
IV-05 Rik Schoemaker Modelling Ordered Categorical Allergic Rhinitis Scores in an Environmental Exposure Unit Study Thursday 15:05-16:20 |
IV-06 Nelleke Snelder Quantitative understanding of drug effects on the interrelationship between mean arterial blood pressure, cardiac output and total peripheral resistance Thursday 15:05-16:20 |
IV-07 Yi SoJeong Population Pharmacokinetics of a Novel Proton Pump Inhibitor, Drug Y, in Healthy Volunteers Thursday 15:05-16:20 |
IV-08 Alexander Solms Modelling Inter-Individual Variability in PBPK Models and Deriving Mechanistic Covariate Models for PopPK Thursday 15:05-16:20 |
IV-09 Ivy Song Applications of Population Pharmacokinetic Modeling during Phase2B to Support the Clinical Development of Dolutegravir (DTG, S/GSK1349572) Thursday 15:05-16:20 |
IV-10 Ivy Song Dose Selection of Dolutegravir (DTG, S/GSK1349572) in Pediatric Studies Thursday 15:05-16:20 |
IV-11 Alexandre Sostelly Characterization of the interaction between irinotecan, SN-38 and MBLI-87, a new BCRP inhibitor, with a multi-scale semi-mechanistic PKPD model Thursday 15:05-16:20 |
IV-12 Joe Standing Methods for Optimising Neonatal Antimicrobial Use: Time- and Concentration-Dependent Agents Thursday 15:05-16:20 |
IV-13 Andreas Steingoetter A population pharmacokinetic model for Gd-DTPA in DCE-MRI Thursday 15:05-16:20 |
IV-14 Doerthe Steller Extension of Continuous-Time PK/PD Markov Models to Published Count Data Thursday 15:05-16:20 |
IV-15 Ahmed Suleiman A Mixed-Effects Markov Model for Characterizing the Time Course of the Transitions between Different Extrapyramidal Side Effects Severity Levels Thursday 15:05-16:20 |
IV-16 Elin Svensson Mega-model of nevirapine population pharmacokinetics Thursday 15:05-16:20 |
IV-17 Svetlana Vinogradova Applying of population PK-PD methods to analysis of viral dynamics of HIV/HCV-Coinfected Sustained Virological Responders and Nonresponders treated with PEG-IFN Thursday 15:05-16:20 |
IV-18 Ami Fazlin Syed Mohamed Pharmacokinetic-Pharmacodynamic Modelling of Pre-existing and Emerging Resistance of Pseudomonas aeruginosa to Colistin Thursday 15:05-16:20 |
IV-19 Stina Syvänen Quinidine Microdialysis Reveals Altered P-glycoprotein Function in Epileptic Rats in the Brain Parenchyma Rather than at the Blood-Brain Barrier Thursday 15:05-16:20 |
IV-20 Amit Taneja Optimisation of Screening Experiments for the Assessment of Analgesic Effects Thursday 15:05-16:20 |
IV-21 Sonya Chapman The Importance of Enterohepatic Recirculation in the Disposition of Pravastatin and Rosuvastatin: A Physiologically-Based Pharmacokinetic Modelling Approach Thursday 15:05-16:20 |
IV-22 David Ternant Influence of the FcγRIIIa genetic polymorphism on the effect of antithymocyte globulins on lymphocyte populations in kidney transplantation Thursday 15:05-16:20 |
IV-23 Nadia Terranova A non parametric population approach for selecting biomarkers of a drug action Thursday 15:05-16:20 |
IV-24 Donato Teutonico Multivariate patient simulation for clinical trial optimization in COPD Thursday 15:05-16:20 |
IV-25 Michel Tod A meta-analysis regression model for quantitative prediction of the impact of polymorphism on drug exposure Thursday 15:05-16:20 |
IV-26 Dorota Tomalik-Scharte Evaluation of Circadian Rhythms in Hepatic CYP3A4 Activity Using Population Pharmacokinetics of Midazolam Thursday 15:05-16:20 |
IV-27 Mirjam Trame Busulfan Dosing in Children: Body Weight versus Body Surface Area or Allometric Body Weight Dosing Thursday 15:05-16:20 |
IV-29 Kuenhi Tsai Evaluating Bootstrap Methods in Nonlinear Mixed Effect Models (NMEM) Using a PK Model Thursday 15:05-16:20 |
IV-30 Karin Tunblad A pharmacokinetic/pharmacodynamic analysis of central and peripheral effects of GSK3 inhibitors Thursday 15:05-16:20 |
IV-31 Wanchana Ungphakorn Population Pharmacokinetics and Use of Monte Carlo Simulation To Determine Optimal Dosing Regimen of Oral Ciprofloxacin in Paediatric Patients with Severe Malnutrition Thursday 15:05-16:20 |
IV-32 Pavan Vajjah Effect of decontamination on the pharmacokinetics and pharmacodynamics of venlafaxine in overdose Thursday 15:05-16:20 |
IV-33 Pyry Välitalo Pharmacokinetics of Oxycodone in Labouring Women With Preliminary Estimates of Neonatal Exposure Thursday 15:05-16:20 |
IV-34 Marta Valle Effect of Ritonavir Concentrations on Atazanavir Pharmacokinetics: Population Pharmacokinetic Analysis Thursday 15:05-16:20 |
IV-35 Georgia Valsami Assessment of dosage regimens of tigecycline in hospitalised patients Thursday 15:05-16:20 |
IV-36 Piet van der Graaf Towards a Thorough Preclinical QT (“TpQT”) study paradigm: Pharmacokinetic-Pharmacodynamic (PKPD) Modelling of QTc Effects of Moxifloxacin in Cynomolgus Monkeys Thursday 15:05-16:20 |
IV-37 Piet van der Graaf Application of a Multiscale Physiologically-Based Bone and Calcium Systems Model to Guide the Development of GnRH receptor modulators for the Management of Endometriosis Thursday 15:05-16:20 |
IV-38 Jan-Stefan van der Walt The effect of nevirapine-based antiretroviral therapy on the population pharmacokinetics of artemether and dihydroartemesinin in HIV-infected adults Thursday 15:05-16:20 |
IV-39 Sven van Dijkman Optimal design for a dexmedetomidine pharmacokinetic trial in mechanically ventilated neonates with single organ respiratory failure. Thursday 15:05-16:20 |
IV-40 Erno van Schaick PK-PD modelling of bone density and turnover effects of denosumab based on a circular model of bone remodelling Thursday 15:05-16:20 |
IV-41 Georgios Vlasakakis The impact of modified-release formulations on bridging of pharmacokinetic data from adults to children Thursday 15:05-16:20 |
IV-42 Max von Kleist A Mathematical Modelling Framework to Assess the Impact of Nevirapine-based Prophylaxis on vertical HIV Transmission Thursday 15:05-16:20 |
IV-43 Camille Vong Optimal Design of Anticancer Regimens Thursday 15:05-16:20 |
IV-44 Katarina Vučićević Population Pharmacokinetic Modelling of Amikacin in Neonates Thursday 15:05-16:20 |
IV-45 Toshihiro Wajima Pharmacokinetic/pharmacodynamic Modeling and Long-term Simulation of Dolutegravir (DTG, S/GSK1349572) in Integrase Resistant Patients with a Simple Viral Dynamic Model Thursday 15:05-16:20 |
IV-46 Chenguang Wang The allometric exponent for propofol clearance varies with age Thursday 15:05-16:20 |
IV-47 Thomas Wendl Development of a physiologically-based pharmacokinetic (PBPK) model for Moxifloxacin and its metabolites in healthy adults Thursday 15:05-16:20 |
IV-48 Thomas Wendl Modeling of renal failure, dialysis, inhalation and mechanical ventilation: Development of a whole-body physiologically-based pharmacokinetic (PBPK) model for ICU patients with and without renal failure receiving inhalatively administered Amikacin via a tracheal tube. Thursday 15:05-16:20 |
IV-49 Pawel Wiczling Pharmacokinetics and Pharmacodynamics of Propofol in ASA III Patients Undergoing Abdominal Aortic Surgery Thursday 15:05-16:20 |
IV-50 Mélanie Wilbaux Population K-PD modeling of CA125 and tumor size kinetics in relapsed ovarian cancer patients Thursday 15:05-16:20 |
IV-51 Christian Woloch Population Pharmacokinetics of Mefloquine and its Major Metabolite in Healthy Volunteers. Thursday 15:05-16:20 |
IV-52 Dan Wright Development of a Bayesian forecasting method for warfarin dose individualisation Thursday 15:05-16:20 |
IV-53 Rujia Xie Model based meta-analysis (MBMA) to support the development of decision criteria in dental pain studies Thursday 15:05-16:20 |
IV-54 Hongmei Xu Mechanism-based Modelling of the Antagonism between Polymyxin B and Levofloxacin against Pseudomonas aeruginosa using Mono- and Combination Therapy Thursday 15:05-16:20 |
IV-55 Shuying Yang Predicting long term Placebo response based on short term observations:Meta-Analysis on FEV1 Response in Asthma Trials Thursday 15:05-16:20 |
IV-56 Shuying Yang Using Placebo FEV1 Response to Improve the efficiency of clinical trials in Asthma Thursday 15:05-16:20 |
IV-57 James Yates Population PK/PD modelling of AZD9773 in patients with severe sepsis. Thursday 15:05-16:20 |
IV-58 James Yates Characterisation of Xenograft Response to Docetaxel by Nonlinear Mixed Effects Modelling Thursday 15:05-16:20 |
IV-59 Stefan Zajic Semi-mechanistic PK/PD Model of the Effect of Odanacatib, a Cathepsin K Inhibitor, on Bone Turnover to Characterize Lumbar Spine and Distal Forearm Bone Mineral Density in A Phase IIb Study of Postmenopausal Women Thursday 15:05-16:20 |
IV-61 Miren Zamacona Model based approach to inform early clinical development for a biologic Thursday 15:05-16:20 |
IV-62 Chao Zhang Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-infected Adults Thursday 15:05-16:20 |
IV-63 Jianping Zhang Population Pharmacokinetics of Lapatinib in Cancer Patients Thursday 15:05-16:20 |
IV-64 Wei Zhao Individualized therapy and Bayesian estimator of ganciclovir exposure after oral administration of valganciclovir in pediatric renal transplant patients Thursday 15:05-16:20 |
IV-65 Kirill Zhudenkov Pharmacokinetics of PEG-IFN Alpha in HCV Infected Patients Thursday 15:05-16:20 |
IV-66 Simbarashe Peter Zvada Population Pharmacokinetics of Isoniazid in Children with Pulmonary Tuberculosis Thursday 15:05-16:20 |